PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28681115-5	2017	Results have already been obtained from phase 3 studies for tofacitinib, a Janus kinase inhibitor as well as for the antibodies brodalumab, bimekizumab and ABT-122 that inhibit the IL17-signaling pathway.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	156-159	interleukin 17A	Homo sapiens	181-185	
29364523-1	2018	ABT-122 is an IgG1 dual-variable domain immunoglobulin that specifically blocks TNF-alpha and IL-17A.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	0-3	interleukin 17A	Homo sapiens	94-100	
29855172-9	2018	CONCLUSION: Over the 12-week study period, dual inhibition of TNF and IL-17A with ABT-122 produced a safety profile consistent with that of adalimumb used for inhibition of TNF alone.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	82-85	interleukin 17A	Homo sapiens	70-76	
29855175-0	2018	Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	18-21	interleukin 17A	Homo sapiens	56-71	
29855175-1	2018	OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	53-56	interleukin 17A	Homo sapiens	97-112	
29855175-1	2018	OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	53-56	interleukin 17A	Homo sapiens	114-120	
30032191-0	2018	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	67-70	interleukin 17A	Homo sapiens	46-61	
29855175-10	2018	CONCLUSION: Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	55-58	interleukin 17A	Homo sapiens	43-49	
28941216-0	2017	Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	46-49	interleukin 17A	Homo sapiens	84-98	
28941216-2	2017	ABT-122 is a novel dual variable domain immunoglobulin that selectively and simultaneously targets human TNF and IL-17A.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	0-3	interleukin 17A	Homo sapiens	113-119	
28941216-13	2017	CONCLUSION: The results of these phase I studies suggest that dual neutralization of TNF and IL-17 with ABT-122 has characteristics acceptable for further exploration of therapeutic potential in TNF- and IL-17A-driven immune-mediated inflammatory diseases.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	104-107	interleukin 17A	Homo sapiens	93-98	
28941216-13	2017	CONCLUSION: The results of these phase I studies suggest that dual neutralization of TNF and IL-17 with ABT-122 has characteristics acceptable for further exploration of therapeutic potential in TNF- and IL-17A-driven immune-mediated inflammatory diseases.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	104-107	interleukin 17A	Homo sapiens	204-210